Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan Plus Pertuzumab in Neoadjuvant HER2-positive Breast Cancer
NCT07047755Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab rezetecan in HER2-positive breast cancer, sponsored by Henan Cancer Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07047755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047755.